JP2024506382A5 - - Google Patents

Info

Publication number
JP2024506382A5
JP2024506382A5 JP2023548868A JP2023548868A JP2024506382A5 JP 2024506382 A5 JP2024506382 A5 JP 2024506382A5 JP 2023548868 A JP2023548868 A JP 2023548868A JP 2023548868 A JP2023548868 A JP 2023548868A JP 2024506382 A5 JP2024506382 A5 JP 2024506382A5
Authority
JP
Japan
Prior art keywords
approximately
pharmaceutical composition
less
decanoate
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506382A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016278 external-priority patent/WO2022174134A1/en
Publication of JP2024506382A publication Critical patent/JP2024506382A/ja
Publication of JP2024506382A5 publication Critical patent/JP2024506382A5/ja
Pending legal-status Critical Current

Links

JP2023548868A 2021-02-15 2022-02-14 アビラテロンプロドラッグ Pending JP2024506382A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149550P 2021-02-15 2021-02-15
US63/149,550 2021-02-15
PCT/US2022/016278 WO2022174134A1 (en) 2021-02-15 2022-02-14 Abiraterone prodrugs

Publications (2)

Publication Number Publication Date
JP2024506382A JP2024506382A (ja) 2024-02-13
JP2024506382A5 true JP2024506382A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=80625499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548868A Pending JP2024506382A (ja) 2021-02-15 2022-02-14 アビラテロンプロドラッグ

Country Status (6)

Country Link
US (3) US11957696B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291159A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506382A (cg-RX-API-DMAC7.html)
CN (1) CN117120034A (cg-RX-API-DMAC7.html)
CA (1) CA3207282A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022174134A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319363A (en) 2017-01-31 2025-05-01 Arvinas Operations Inc Cervalon ligands and bifunctional compounds containing them
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
WO2021127443A1 (en) 2019-12-19 2021-06-24 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations
CN119136813A (zh) 2022-03-01 2024-12-13 普洛拉治疗公司 阿比特龙前药
EP4608404A1 (en) * 2022-10-24 2025-09-03 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116046950A (zh) * 2023-01-18 2023-05-02 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种检测醋酸阿比特龙中5种杂质的方法
WO2024186523A2 (en) * 2023-03-07 2024-09-12 Board Of Regents, The University Of Texas System Glucocorticoid receptor antagonists for cancer treatment

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
AU7736300A (en) * 1999-09-30 2001-04-30 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011066582A1 (en) 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
BR112013017635A2 (pt) 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
CN104066744B (zh) 2011-10-10 2017-03-22 扎克系统公司 用于制备17‑取代的甾体的方法
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2013159225A1 (en) 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
US20140011992A1 (en) 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
CA2898573A1 (en) 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
TWI686212B (zh) 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
CN104017045B (zh) 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016044701A1 (en) 2014-09-18 2016-03-24 Iceutica Inc. Abiraterone acetate formulation and methods of use
CN104356191A (zh) 2014-09-29 2015-02-18 上海延安药业(湖北)有限公司 阿比特龙单琥珀酸酯及其制备方法
CN106061990B (zh) 2014-11-28 2019-09-10 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
CN104710499A (zh) 2015-02-15 2015-06-17 重庆医药工业研究院有限责任公司 一种丙酸阿比特龙的晶型及其制备方法
ES2954596T3 (es) 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
JP6842474B2 (ja) 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. ステロイド系化合物、当該化合物を含む組成物及びその使用
US10717762B2 (en) 2016-10-11 2020-07-21 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN106977577A (zh) 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
JOP20200072A1 (ar) * 2017-10-11 2020-04-29 Janssen Oncology Inc طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
JP2022523704A (ja) 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN113825514A (zh) * 2019-03-18 2021-12-21 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs
CN113929727A (zh) 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Similar Documents

Publication Publication Date Title
JP4680891B2 (ja) 許容可能な血清中テストステロン・レベルを信頼性高く達成するための方法及び医薬組成物
CN1222292C (zh) 氟维司群制剂
EP3265127B1 (en) Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor
EP1313511B1 (en) Testosterone ester formulation for human use
BR112012025961B1 (pt) Composição farmacêutica oral
JP2024506382A (ja) アビラテロンプロドラッグ
JP2023539371A5 (cg-RX-API-DMAC7.html)
JP2024533332A5 (cg-RX-API-DMAC7.html)
WO2023167783A1 (en) Abiraterone decanoate prodrugs and use in therapy
RU2024129008A (ru) Пролекарства абиратерона деканоата и их применение в терапии
HK40120426A (en) Abiraterone prodrugs
HK1099230A (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Sternberg New targets and drugs in prostate cancer
HK1069325B (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
HK1248128B (en) Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor